Pharma’s return to growth: EvaluatePharma

On 26 June, EvaluatePharma released their “World Preview: 2013” report which forecasts a return to return to growth of the global biopharma market – in contrast to their prediction of unprecedented market contraction in the 2012 report.  It seems that we … Continue reading

Astellas discontinue darexaban development citing intensified competition

The oral anticoagulant market is one of the few primary care markets expected to grow significantly in the next few years, with a number of the new oral thrombin inhibitors and factor Xa inhibitors set to generate peak sales well in excess of $1billion.  … Continue reading